I don't think we can expect to get by without further cap raises. But this will help to space them out a bit and potentially reduce the amount required.
This is an extension of the 43.5% R&D expenditure rebate from that conducted in Oz to all R&D expenditure.
So for the next $100m we spend on R&D, regardless of where it is carried out, we'll get $44m in rebates.
Best thing is we don't need to limit trials and pre-clinical work to Oz to secure R&D rebates. Very cool.
Credit to James and the team. Surely there are more sources of non-dilutive funding available, given the seriousness of the public health issue Recce is seeking to address.
.
(20min delay)